Fulgent Genetics Inc
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
FLGT$26.15+10.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Revenue | $71,743 | $84,687 | $207,256 | $218,708 |
| Cost of revenue | 44,972 | 44,843 | 131,890 | 139,481 |
| Gross profit | 26,771 | 39,844 | 75,366 | 79,227 |
| Operating expenses: | ||||
| Research and development | 11,783 | 10,014 | 36,703 | 29,488 |
| Selling and marketing | 9,124 | 10,161 | 26,708 | 30,967 |
| General and administrative | 20,950 | 17,498 | 63,765 | 57,293 |
| Amortization of intangible assets | 1,993 | 1,957 | 5,973 | 5,887 |
| Total operating expenses | 43,850 | 39,630 | 133,149 | 123,635 |
| Operating (loss) income | (17,079) | 214 | (57,783) | (44,408) |
| Other income (expenses): | ||||
| Interest income | 8,090 | 6,472 | 23,181 | 15,802 |
| Interest expense | (14) | (70) | 210 | (625) |
| Impairment of available-for-sale debt securities | (10,073) | — | (10,073) | — |
| Other income, net | 544 | 244 | 554 | 342 |
| Total other (expense) income, net | (1,453) | 6,646 | 13,872 | 15,519 |
| (Loss) income before income taxes | (18,532) | 6,860 | (43,911) | (28,889) |
| (Benefit from) provision for income taxes | (3,838) | 20,326 | (6,281) | 12,016 |
| Net loss from consolidated operations | (14,694) | (13,466) | (37,630) | (40,905) |
| Net loss attributable to noncontrolling interests | 46 | 359 | 810 | 1,229 |
| Net loss attributable to Fulgent | $(14,648) | $(13,107) | $(36,820) | $(39,676) |
| Net loss per common share attributable to Fulgent | ||||
| Basic | $(0.48) | $(0.44) | $(1.22) | $(1.33) |
| Diluted | $(0.48) | $(0.44) | $(1.22) | $(1.33) |
| Weighted-average common shares: | ||||
| Basic | 30,416 | 30,013 | 30,095 | 29,789 |
| Diluted | 30,416 | 30,013 | 30,095 | 29,789 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.